

Proteomics: Technologies and Global Markets

Market Research Report | 2022-12-05 | 384 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

The study's scope covers MS instruments, consumables, workflow products, planar arrays, bead arrays, and LOACs. It also covers the research, drug discovery and development, diagnostics, and applied end-user market segments. The main geographical markets-North America, Europe, Asia-Pacific, and Rest of the World (ROW)-are included.

The MS market is covered by instrument type, MS consumables, and product type and end-user markets. The biochip market is covered by biochip type and the end-user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type and for cancer by indication. This report provides the current market sizes for these segments, as well as their forecasted growth to 2027.

Technology status and forces driving the market are discussed and analyzed. Factors that influence each market are also highlighted, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs, and competitive trends.

Key industry acquisitions and strategic alliances are given for the five-year period from 2021 through 2027.

This report examines the main patent trends within the industry and profiles proteomics companies.

Report Includes:

- 149 data tables and 97 additional tables

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

- An up-to-date overview of the global markets for proteomics and related technologies
- Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the upcoming market potential for the global proteomics industry, growth driving factors, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and market forecast for proteomics in value (USD millions) terms, and their corresponding market share analysis by platform technology, end-user application, and region
- In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in proteomics, and COVID-19 impact on the market for proteomics
- Insight into recent industry structure for proteomics technologies, competitive aspects of each product segments, major growth strategies, and company value share analysis based on their segmental revenues
- Updated information on key mergers and acquisition deals, agreements, partnerships, collaborations and product launches within the global proteomics industry
- Profile descriptions of the leading proteomics manufacturers, including Agilent, Danaher Corp., GlaxoSmithKline PLC, PerkinElmer Inc., Qiagen GmbH, and Sanofi.

Executive Summary

Summary:

In May 2014, two independent research groups, one in the U.S. and India, and the other in Germany, published the first drafts of the human proteome, which was based on mass spectrometry data. These maps were the most comprehensive to date and signaled the rapid progress in our understanding of the role of genes and their products, proteins.

Approximately 5 million scientists are working on biological sample preparation in more than 80,000 laboratories globally. Major factors impacting the market are increased spending on research and development in developing economies. China is emerging as a global leader in sequencing and an increasing number of genomics projects run by Chinese agencies and other companies throughout the globe are creating genome libraries. There is also increased interest in personal genetics. Many companies, including Google, are investing in genomics start-ups. Along with this growth in genomics and proteomics, is a growing concern regarding data security and privacy. Personal genomics kits currently sold directly to consumers have become a growing concern for the U.S. Food and Drug Administration (FDA).

The draft human proteome signaled the coming of age of proteomics, a field that is rapidly transitioning from research and development application to more applied fields including diagnostics. The two key proteomics technologies-mass spectrometry and biochips-are benefiting from an explosion of new proteomics content from the large-scale genomic and proteomic initiatives. For instance, according to the Journal of Proteome Research, ACS Publications, the Human Proteome Organization (HUPO) has introduced the Proteomics Standards Initiative (PSI) that is exploring software tools and open community standards in proteomics over the last 15 years (from 2002). Further, HUPO is also credited with completing protein parts list for the draft human proteome. In addition, HUPO is also exploring the application of proteomics for integration with genomics and transcriptomics across life sciences and biomedical research. This proteomics content is driving the discovery of new biomarkers that are important in disease diagnostic processes such as cancer diagnostics, myocardial infarction, congestive heart failure, and others.

Novel technologies are also driving proteomics applications. For example, increasing miniaturization and integration is occurring in biochip devices, and improvements in mass spectrometry workflow and instruments. These innovations are driving proteomics applications in important markets like drug discovery and development and diagnostics. For instance, in 2017, as per the European Association of Urology, the Israeli Institute of Technology developed a silicon biosensor chip that can identify the best antibiotics in just a few hours instead of days and can help in treating a bacterial infection. Furthermore, in 2017, the Georgia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Institute of Technology presented that replacing conventional power supplies with Triboelectric Nano-generators (TENG) for charging molecules can boost up sensitivity of mass spectrometers and can also help in identification of small volumes.

Table of Contents:

Table of Contents

Chapter 1 Introduction

1.1 Study Goals and Objectives

1.2 Reasons for Doing the Study

1.3 What's New in This Update?

1.4 Scope of Report

1.5 Intended Audience

1.6 Methodology

1.7 Information Sources

1.8 Analyst's Credentials

1.9 BCC Custom Research

1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

3.1 Proteomic Technologies

3.2 Scope of Report

3.3 Proteomics Market

3.4 Driving Forces for Proteomics Industry Growth

3.4.1 Drivers

3.4.2 Restraints

3.4.3 Opportunities

3.4.4 Challenge

3.4.5 Proteomics Industry

Chapter 4 COVID 19 Impact on Proteomics Market

4.1 Overview

4.2 COVID-19 Crisis

4.3 Impact on Market

4.4 Current Outlook

4.4.1 Implications on Cancer Diagnosis

4.4.2 Key Reasons for Impact of COVID-19

Chapter 5 Proteomics Technologies

5.1 Introduction

5.2 MS-Based Proteomics Technologies

5.2.1 Sample Preparation Assays

5.2.2 Tagging/Affinity Methods

5.2.3 Utility of Proteomics to Identify Biomarkers

5.2.4 MS Instruments and Consumables

5.3 Biochip-Based Proteomics Technologies

5.3.1 Multiplex Proteomics Systems

5.3.2 Proteogenomics

5.3.3 Recent Advances in Proteomics Technologies

Chapter 6 Proteomics Applications in Drug Discovery and Development

6.1 Target Discovery

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2 Lead Identification
- 6.3 Lead Optimization
- 6.4 Preclinical Studies
- Chapter 7 Proteomics Scientific Initiatives
- Chapter 8 Clinical Proteomics Applications
 - 8.1 Applications in Cancer
 - 8.1.1 Overview
 - 8.1.2 Bladder Cancer
 - 8.1.3 Breast Cancer
 - 8.1.4 Colorectal Cancer
 - 8.1.5 Gastric Cancer
 - 8.1.6 Kidney Cancer
 - 8.1.7 Lung Cancer
 - 8.1.8 Lymphomas
 - 8.1.9 Ovarian Cancer
 - 8.1.10 Pan-Cancer
 - 8.1.11 Prostate Cancer
 - 8.1.12 Thyroid Cancer
 - 8.1.13 Other Cancers
 - 8.2 Infectious Diseases
 - 8.3 Diabetes
 - 8.4 Neurological Disorders
 - 8.4.1 Alzheimer's Disease
 - 8.4.2 Schizophrenia
 - 8.5 Immune Diseases
 - 8.5.1 HLA Typing
 - 8.5.2 Autoimmune Disease
 - 8.6 Cardiovascular Disease
 - 8.7 Preeclampsia
- Chapter 9 Proteomics Industry
 - 9.1 Industry Acquisitions
 - 9.2 Industry Strategic Alliances
 - 9.3 Mass Spectrometry Industry
 - 9.4 Chromatography Industry
 - 9.5 Proteomics-Based Drug Discovery and Development Industry
 - 9.6 Proteomics Biochip Industries
 - 9.6.1 Peptide Microarray Industry
 - 9.6.2 High-Density Protein Array Industry
 - 9.7 Antibody Microarray Industry
 - 9.8 China's Biochip Industry
 - 9.9 Lab-on-a-Chip Proteomics Industry
 - 9.10 Chemical Proteomics Industry
 - 9.11 Antibody Reagent Industry
 - 9.12 Multiplex Protein Diagnostics Industry
 - 9.13 Dried Blood Spotting Proteomics Industry
 - 9.14 Single Cell Proteomics Industry
- Chapter 10 Proteomics Markets

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1 Driving Forces of Proteomics Industry Growth
- 10.2 Global Proteomics Markets
- 10.3 Market Summary
- 10.4 Research Market
- 10.5 Drug Discovery and Development Market
- 10.6 Proteomics Diagnostic Market
- 10.7 Mass Spectrometry-Based Proteomics Market
- 10.8 Biochip-Based Proteomics Market
- Chapter 11 Proteomics Market by Geographic Segmentation
 - 11.1 North America
 - 11.1.1 United States
 - 11.1.1 Canada
 - 11.2 Europe
 - 11.2.1 Impact of Brexit
 - 11.2.2 United Kingdom
 - 11.2.3 Germany
 - 11.2.4 France
 - 11.2.5 Italy
 - 11.2.6 Spain
 - 11.2.7 Rest of Europe
 - 11.3 Asia-Pacific
 - 11.3.1 China
 - 11.3.2 Japan
 - 11.3.3 India
 - 11.3.4 South Korea
 - 11.3.5 Australia
 - 11.3.6 Rest of Asia-Pacific
 - 11.4 Rest of the World (RoW)
- Chapter 12 Proteomics Patents
 - 12.1 U.S. Proteomics Patents
 - 12.2 Protein Array Patents
 - 12.2.1 Lab-on-a-Chip Patents
 - 12.2.2 Mass Spectrometry Patents
- Chapter 13 Competitive Landscape
 - 13.1 Genomics and Proteomic Tools/Technologies
 - 13.1.1 Sequencing Technologies
 - 13.1.2 PCR Technology
 - 13.1.3 Nucleic Acid Purification and Separation
 - 13.1.4 Nucleic Acid Separation Technologies
- Chapter 14 Company Profiles
 - ABCODIA LTD.
 - ACTIVX BIOSCIENCES INC.
 - ADVANCED PROTEOME THERAPEUTICS INC.
 - AGILENT TECHNOLOGIES INC.
 - APPLIED PROTEOMICS
 - ARRAYIT CORP.
 - ASTUTE MEDICAL INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

AVACTA LIFE SCIENCES LTD.
AYOXXA BIOSYSTEMS GMBH
BECTON, DICKINSON AND CO.
BIOCARTIS NV
BIODESIX INC.
BIOGNOSYS AG
BIOMERIEUX SA
BIO-RAD LABORATORIES INC.
BIO-TECHNE INC.
BRUKER CORP.
CAMBRIDGE PROTEIN ARRAYS LTD.
CHARLES RIVER LABORATORIES INTERNATIONAL INC.
CRYSTALGENOMICS INC.
DANAHER CORP.
EPICYEPHER INC.
EVOTEC AG
GENERAL ELECTRIC CO.
GLAXOSMITHKLINE PLC
GL SCIENCES INC.
ILLUMINA INC.
IMMUNOVIA AB
IMTAKT CORP.
INTEGRATED DIAGNOSTICS HOLDING
INDI MOLECULAR
LABCYTE INC.
LIMINAL BIOSCIENCES INC.
MERCK & CO. INC.
MERCK KGAA
MRM PROTEOMICS INC.
MYCARTIS
MYRIAD GENETICS INC.
NEWOMICS INC.
NIRMIDAS BIOTECH INC.
OLINK BIOSCIENCE
OPKO HEALTH INC.
PERKINELMER INC.
PERSONALIZED CANCER THERAPY INC.
PFIZER INC.
PHENOMENEX INC.
PRESSURE BIOSCIENCES INC.
PROTAGEN AG
PROTEA BIOSCIENCES INC.
PROTEOCYTE DIAGNOSTICS INC.
PROTEOGENIX
PROTEOME SCIENCES PLC
PROTEOMICS INTERNATIONAL PTY LTD.
PYC THERAPEUTICS. (FORMERLY PHYLOGICA LTD.)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

QIAGEN N.V.
QUANSYS BIOSCIENCES
QUANTERIX INC.
QUEST DIAGNOSTICS INC.
REPLIGEN CORP.
ROCHE (F. HOFFMANN-LA ROCHE LTD.)
SAMDI TECH INC.
SANOFI
SERA PROGNOSTICS
SHIMADZU CORP.
SHISEIDO COMPANY LTD.
SHOWA DENKO KK
SINGULEX INC.
SISCAPA ASSAY TECHNOLOGIES INC.
SOMALOGIC INC.
SPOTON CLINICAL DIAGNOSTICS LTD.
SQI DIAGNOSTICS
STANDARD BIOTOOLS INC. (FORMERLY FLUIDIGM)
SYNAGEVA BIOPHARMA (ACQUIRED BY ALEXION PHARMACEUTICALS INC.)
T2 BIOSYSTEMS
THERMO FISHER SCIENTIFIC INC.
THORNE DIAGNOSTICS INC.
TOSOH CORP.
TRAJAN SCIENTIFIC AND MEDICAL
UNIVERSAL BIOSENSORS LTD.
VG LIFE SCIENCES INC.
WATERS CORP.
XENCOR INC.
YMC CO. LTD.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Proteomics: Technologies and Global Markets

Market Research Report | 2022-12-05 | 384 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

